Phase IV study to evaluate the safety and efficacy of maribavir in reducing Epstein–Barr virus in young adult kidney transplant recipients.

The requested reference [dad7e44da6af212dea959801e6b64b5cc6980c2f] no longer exists in our database. It has been replaced by the current reference: [4262e9377fe36e531703a7bc975649e1c1359b9b]

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2026
This article has no abstract
Epistemonikos ID: 6a4b87542d5bbf17ad22376c6027bbb9b388c97a
First added on: Nov 01, 2026